Therapeutic progress on the treatment of hepatitis B recurrence after liver transplantation
- VernacularTitle:治疗肝移植术后乙肝复发的药物进展
- Author:
Chunge WANG
;
Yi ZHANG
;
- Publication Type:Journal Article
- Keywords:
liver transplantation;
hepatitis B recurrence;
antivirus therapy
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2000;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B recurrence is an important factor to show whether liver transplantation is successful or not. Recrrrence rate is nearly 80% in the patients liver transplantation, and HBV reinfection is the main cause of death. After the operation, HBV may copy very quickly, because of taking in immunosuppressant therapy and graft diseases develop rapidly. Recently, the exploitation and application of therapy has become a focus. Now the drugs of preventing and treating HBV reinfection are mainly sorted into passive immunity agents(Hepatitis B immunoglobulin) and antivirus therapeutic agents(interferon and nucleotide analog antivirus drugs, etc.). Lamivudine is considered the most promising new drug of treating HBV infection. This article introduced the therapeutic characteristic of these drugs.
